Aurora Cannabis and MedReleaf Australia Launch New THC Cannabis Product Line for Medical Patients

LOS ANGELES– Canadian company Aurora Cannabis Inc., known for its efforts to open up the world to cannabis, has announced the launch of IndiMed Tempo 26 in partnership with MedReleaf Australia. The new range of higher THC dried cannabis products will be available to qualified patients under the MedReleaf Concession Scheme (MCS), expanding the variety of medical cannabis products available to Australian patients. The move is aimed at giving doctors greater control and choice in prescribing medical cannabis treatment.

CEO of Aurora Cannabis, Miguel Martin, commented on the launch, saying, “We are strongly committed to our patient-first approach to cannabis and ensuring access to medical patients in Australia and around the world.” The MCS was created by Aurora and MedReleaf to improve patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme (PBS). It provides compassionate pricing for patients with certain concession cards, including Pensioner Concession Cards, Commonwealth Seniors Health Cards, Health Care Cards, and Veterans Cards (DVA).

MedReleaf CEO, Russell Harding, noted that the heavily discounted products offered through the MCS widen the choice for prescriptions and significantly improve access for disadvantaged Australian patients struggling with debilitating health conditions. The products are cultivated and manufactured in Aurora’s GMP accredited facilities and made available for doctors to prescribe via the TGA’s Special Access Scheme.

The new product line is part of Aurora’s 10% ownership stake in MedReleaf Australia, which is a fully licensed private company. The two companies work together to provide Australian patients with innovative Aurora-branded products, including dried flower, oils, soft gels, and resin cartridges. The launch of IndiMed Tempo 26 marks a significant milestone in Aurora’s efforts to expand its medical cannabis portfolio and improve access to medical cannabis for patients in Australia and beyond.